Literature DB >> 27780480

Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in Germany.

C Schwarze-Zander1,2, R Draenert3,4, C Lehmann2,5, M Stecher2,5, C Boesecke1,2, S Sammet3,4, J C Wasmuth1,2, U Seybold3,4, D Gillor2,5, U Wieland6, T Kümmerle2,5, C P Strassburg1,2, A Mankertz7, A M Eis-Hübinger8, G Jäger9, G Fätkenheuer2,5, J R Bogner3,4, J K Rockstroh1,2, J J Vehreschild2,5.   

Abstract

Measles, mumps, rubella (MMR) and varicella zoster virus (VZV) infection can cause serious diseases and complications in the HIV-positive population. Due to successful vaccination programmes measles, mumps and congenital rubella syndrome has become neglected in Germany. However, recent outbreaks of measles have occurred from import-associated cases. In this cross-sectional study the serostatus for MMR and VZV in 2013 HIV-positive adults from three different university outpatient clinics in Bonn (n = 544), Cologne (n = 995) and Munich (n = 474) was analysed. Sera were tested for MMR- and VZV-specific immunglobulin G antibodies using commercial immunoassays. Seronegativity was found in 3% for measles, 26% for mumps, 11% for rubella and 2% for VZV. Regarding MMR, 35% of patients lacked seropositivity against at least one infectious agent. In multivariable analysis younger age was strongly associated with seronegativity against all four viruses, measles, mumps, rubella (P < 0·001, P < 0·001 and P = 0·001, respectively) and VZV (P = 0·001). In conclusion, there is high need for MMR and VZV vaccination in people living with HIV in Germany born in 1970 or later. Thus, systematic MMR and VZV antibody screening and vaccination should be implemented in the HIV-positive population to prevent serious disease and complications of vaccine-preventable diseases.

Entities:  

Keywords:  HIV; MMR; VZV; serology

Mesh:

Substances:

Year:  2016        PMID: 27780480      PMCID: PMC9507547          DOI: 10.1017/S095026881600217X

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  21 in total

1.  Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students.

Authors:  Sabine Wicker; Holger F Rabenau; René Gottschalk; Hans Wilhelm Doerr; Regina Allwinn
Journal:  Med Microbiol Immunol       Date:  2007-02-02       Impact factor: 3.402

Review 2.  Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity.

Authors:  Pippa Scott; William J Moss; Zunera Gilani; Nicola Low
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

3.  Measles seroprevalence and vaccine response in HIV-infected adults.

Authors:  M R Wallace; D G Hooper; S J Graves; J L Malone
Journal:  Vaccine       Date:  1994-10       Impact factor: 3.641

4.  Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults.

Authors:  James Molton; Colette Smith; Shelley Chaytor; Peter Maple; Kevin Brown; Margaret Johnson; Anna Maria Geretti
Journal:  J Infect       Date:  2010-04-18       Impact factor: 6.072

5.  High prevalence of measles seronegativity in adults with HIV infection born in the era of measles vaccination in Northern France.

Authors:  Dorothee Lambert; Moustapha Dramé; Christine Rouger; Veronique Brodard; Yohan Nguyen; Jean Luc Berger; Isabelle Kmiec; Maxime Hentzien; Delphine Lebrun; Roland Jaussaud; Laurent Andreoletti; Firouzé Bani-Sadr
Journal:  AIDS       Date:  2015-01-14       Impact factor: 4.177

6.  The prevalence of measles antibody in human immunodeficiency virus-infected patients in northern California.

Authors:  C A Kemper; M Gangar; G Arias; C Kane; S C Deresinski
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

7.  Prevalence of measles antibodies in adults with HIV infection: possible risk factors of measles seronegativity.

Authors:  C A Kemper; A R Zolopa; J R Hamilton; M Fenstersheib; G Bhatia; S C Deresinski
Journal:  AIDS       Date:  1992-11       Impact factor: 4.177

8.  High need for MMR vaccination in HIV infected adults in Austria.

Authors:  K Grabmeier-Pfistershammer; W Poeppl; H Herkner; V Touzeau-Roemer; Emilia Huschka; A Rieger; H Burgmann
Journal:  Vaccine       Date:  2014-09-06       Impact factor: 3.641

9.  Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART.

Authors:  Pablo F Belaunzarán-Zamudio; Miguel L García-León; Rosa María Wong-Chew; Angelina Villasís-Keever; Jennifer Cuellar-Rodríguez; Juan L Mosqueda-Gómez; Teresa Muñoz-Trejo; Kenia Escobedo; José I Santos; Guillermo M Ruiz-Palacios; Juan G Sierra-Madero
Journal:  Vaccine       Date:  2009-09-30       Impact factor: 3.641

10.  Shift of the 2009-2011 measles outbreak from children to adults: an observational review at the University Hospital of Clermont-Ferrand, France.

Authors:  V Corbin; J Beytout; C Auclair; M Chambon; D Mouly; A Chamoux; H Laurichesse
Journal:  Infection       Date:  2013-06-14       Impact factor: 7.455

View more
  2 in total

1.  Field Test and Validation of the Multiplier Measles, Mumps, Rubella, and Varicella-Zoster Multiplexed Assay System in the Democratic Republic of the Congo by Using Dried Blood Spots.

Authors:  Stephen G Higgins; Nicole A Hoff; Adva Gadoth; Andrew Fusellier; Patrick Mukadi; Vivian Alfonso; Christina Randall; Hayley Ashbaugh; Melanie Poncheri; Reena H Doshi; Sue Gerber; Roger Budd; Robert Wolfert; Russell Williams; Emile Okitolonda-Wemakoy; Jean-Jacque Muyembe-Tamfum; Anne W Rimoin
Journal:  mSphere       Date:  2019-08-14       Impact factor: 4.389

2.  Seropositivity, Risks, and Morbidity From Varicella-Zoster Virus Infections in an Adult PWH Cohort From 2000-2020.

Authors:  Jason Zou; Hartmut B Krentz; Raynell Lang; Brenda Beckthold; Kevin Fonseca; M John Gill
Journal:  Open Forum Infect Dis       Date:  2022-08-09       Impact factor: 4.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.